PA-5108 is under clinical development by PolyActiva and currently in Phase II for Open-Angle Glaucoma. According to GlobalData, Phase II drugs for Open-Angle Glaucoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PA-5108’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PA-5108 is under development for the treatment of open-angle glaucoma. The drug candidate is a latanoprost free acid (FA) sustained release (SR) ocular implant which acts by targeting prostaglandin F2-alpha receptor. It is being developed based on Prezia sustained drug delivery technology.
PolyActiva is a biopharmaceutical company that develops biodegradable ocular implants for ophthalmic indications. It is investigating latanoprost FA SR ocular implant to reduce IOP (intraocular pressure) due to open-angle glaucoma and ocular hypertension and levofloxacin ocular implant to reduce the risk of endophthalmitis caused by ocular (cataract) surgery. The company utilizes its proprietary polymeric prodrug platform technology Prezia, to deliver multiple drugs in a single implant by leveraging its expertise in pharmaceutical, organic and polymer chemistry and enabling site-specific, precise and controlled drug delivery to the eye. It was funded by Brandon Capital’s Medical Research Commercialization Fund (MRCF) and Yuuwa Capital LP. The company operates laboratories in Parkville, Victoria, Australia. PolyActiva is headquartered in Melbourne, Victoria, Australia.
For a complete picture of PA-5108’s drug-specific PTSR and LoA scores, buy the report here.